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Abstract
Background: An algorithm for distinguishing invasive pulmonary aspergillosis (IPA) in critically ill patients (AspICU)
has been proposed but not tested.
Methods: This was a prospective observational study applying the AspICU protocol to patients with positive
Aspergillus culture (PAC group) and those with negative aspergillus culture but positive galactomannan test in
respiratory tract samples (only positive galactomannan (OPG group)). Patients underwent a standardized diagnostic
workup with bronchoscopy, computed tomography (CT), and galactomannan determination in serum and
bronchoalveolar lavage fluid (BALF).
Results: We included 85 patients in the study. Of these, 43 had positive aspergillus cultures and 42 patients had
only a positive galactomannan test. There were no statistically significant differences in baseline characteristics,
underlying conditions or ICU scores between the two groups. The galactomannan titre in BALF was significantly
higher in the positive aspergillus culture (PAC) group (enzyme immunoassay (EIA) 5.9, IQR 3.2–5.7) than in the OPG
group (EIA 1.7, IQR 0.9–4.5) (p < 0.001). Classic features of IPA were detected on CT in 37.5 % and 36.6 % of patients
in the PAC and OPG groups, respectively. There were no statistically significant differences between the PAC and
the OPG group in relation to AspICU or European Organization for the Research and Treatment of Cancer (EORTC)
criteria. A positive aspergillus culture was a stronger trigger for initiating antimycotic treatment than positive BALF
galactomannan: 88.4 % of patients in the PAC group were regarded by clinicians as having IPA and received
antimycotic treatment as opposed to 59.5 % in the OPG group (p = 0.002). The 180-day mortality was 58.1 % in the
PAC group and 59.5 % in the OPG group.
Conclusions: The inclusion of BALF galactomannan as an additional entry criterion for the AspICU clinical algorithm
could increase the diagnostic sensitivity for IPA in ICU patients.
Trial registration: The study was registered at ClinicalTrials.gov (registration number NCT01866020) on 27 May 2013.
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Background
Invasive pulmonary aspergillosis (IPA) is one of the most
common causes of death due to invasive mycoses in the
USA and many other areas [1]. With growing numbers
of immunocompromised patients the incidence of
fungal infections has increased in recent years [1, 2].
There has also been an expansion in the spectrum of
patients at risk of IPA beyond the classic risk groups,
particularly in critically ill patients [3, 4]. In such pa-
tients, chronic obstructive pulmonary disease (COPD),
post-influenza syndrome, cirrhosis of the liver, solid
organ transplantation, chronic granulomatous disease,
and prolonged steroid treatment are all risk factors
for developing IPA [5–7].
The number of patients in intensive care units (ICUs)
with positive Aspergillus culture in respiratory tract
samples increases every year [8], but there is still no
non-invasive gold standard for diagnosing IPA in this
patient group. The European Organization for the Re-
search and Treatment of Cancer/Mycosis Study Group
(EORTC/MSG) criteria were developed for diagnosing
IPA in severely immunocompromised patients and may
not be applicable to critically ill patients in the ICU.
Vandewoude et al. first described the AspICU clinical
algorithm in 2004 [9]. Recently, the AspICU clinical
algorithm has been proposed to discriminate IPA
from Aspergillus colonization in ICU patients with
higher diagnostic utility than existing tests [10]. However,
this algorithm has not been evaluated in a prospective
study. Isolation of Aspergillus from respiratory tract
samples is still often assumed to be colonization (and
therefore ignored), despite the prevalence of invasive
disease of up to 50 % in this group [11]. Therefore,
timely initiation of appropriate antimycotic therapy is
often prevented and this may result in a poor outcome
[12–14]. IPA is one of the most frequently underdiag-
nosed infections in critically ill patients [5, 12, 15] and
remains an important cause of morbidity, mortality and
hospital costs [3, 5, 13, 16].
The AspICU clinical algorithm defines positive As-
pergillus culture in respiratory tract samples as an
entry criterion. Patients with IPA and negative Asper-
gillus culture would therefore not be detected with
this protocol. The AspICU protocol does not include
Aspergillus antigen testing. We suggest that including
the detection of galactomannan in bronchoalveolar lavage
fluid (BALF) into the diagnostic algorithm would increase
its sensitivity.
We therefore designed this study to prospectively
evaluate the AspICU algorithm for critically ill patients
with positive Aspergillus culture and to extend it to
patients with negative Aspergillus culture but a positive
BALF antigen test. In addition, we compared the applica-
tion of AspICU and EORTC/MSG criteria.
Methods
Setting
The University Medical Center Hamburg-Eppendorf is a
tertiary medical center with 1,460 beds that treats about
80,000 in-patients per year. The Department of Intensive
Care includes 11 multidisciplinary ICUs with 132 beds.
Approximately 8000 patients are admitted to the ICUs
each year, with an average length of stay of 4.5 days. The
Department of Intensive Care has units to meet special
post-surgical demands after cardiothoracic, neurosurgi-
cal, trauma or visceral surgery. The department receives
many patients following solid organ or allogeneic stem
cell transplantations. The hospital also has specialized
units for the treatment of brain or multiorgan injury,
and for the treatment of acute respiratory distress syn-
drome (ARDS) using extracorporeal lung-assist and
cardiac-assist devices.
Study design
This was a prospective, observational study. All patients
with a positive culture for Aspergillus species or a posi-
tive galactomannan antigen test from respiratory tract
samples treated in one of the departmental ICUs be-
tween 1 January 2013 and 31 July 2014 were eligible for
participation. In our department, microbiological exami-
nations including galactomannan testing in BALF and
serum are routinely performed in all patients with signs
or symptoms of a respiratory tract infection who exhibit
host factors putting them at risk of fungal infections as
described below. Prior to enrolment, all participants or
their legal representatives gave written informed con-
sent. Patients underwent a standardized diagnostic
workup with computed tomography (CT) of the chest,
flexible bronchoscopy (performed by pulmonologists)
with bronchoalveolar lavage (BAL) guided by the im-
aging results. BALF samples underwent galactomannan
antigen and Aspergillus PCR testing. We also tested
serum for the presence of galactomannan antigen. The
initiation of antimycotic treatment was left to the discre-
tion of the attending physician. The ethics committee of
the Hamburg Chamber of Physicians approved the
study. The study was registered at ClinicalTrials.gov
(registration number NCT01866020).
Microbiological assays
Detection of Aspergillus galactomannan in BALF and
serum samples was performed using the Platelia Aspergillus
enzyme immunoassay (Bio-Rad Laboratories, Munich,
Germany) following the manufacturer’s instructions. Tests
were considered positive at a cutoff index ≥0.5 using
single-sample aliquots. For mycological culture, 5–10 ml
BALF were centrifuged at 3000 G for 5 minutes. The
resulting pellet was re-suspended in 1 ml supernatant and
50–100 μl were inoculated onto Sabouraud dextrose-agar
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with gentamicin and chloramphenicol (Oxoid, Basing-
stoke, UK). Plates were incubated at 30 °C for 14 days and
inspected regularly. Culture isolates were identified by
matrix-assisted laser desorption ionization time-of-flight
(MALDI-TOF) mass spectrometry fingerprinting or in-
ternal transcribed spacer (ITS) sequencing as required.
BALF was tested for the presence of Aspergillus DNA by
real-time polymerase chain reaction (PCR) as described.
Nucleic acids were extracted from 200 ml BALF using the
NucliSENS easyMAG platform (biomérieux, Marcy
L’Etoile, France) with the generic protocol and an elution
volume of 60 μl. Quantitative real-time PCR was carried
out using primers and probes specific for Aspergillus spe-
cies and Aspergillus fumigatus and QuantiFast Pathogen
PCR reagents (Qiagen, Hilden, Germany) on a Lightcycler
480 instrument (F. Hoffmann-La Roche AG, Basel,
Switzerland). The positivity cutoff was set at cycle thresh-
old (Ct) ≤40. PCR inhibition was assessed with an internal
amplification control.
CT scans
CT scans were performed using a 256- or 64-multislice
(MSCT) scanner (Brilliance iCT; Brilliance 64, Philips,
Best, The Netherlands). The standard CT protocol in
our radiology department for patients with suspected
pneumonia is a high-resolution low-dose CT protocol
using the following parameters: collimation 128 × 0.625
mm or 64 × 0.625 mm, tube voltage 120 kV, current-
time product 20–40 mAs, pitch 0.993 or 1.078, slice
thickness 1 mm, increment 0.5 mm. Subsequently, the
acquired data underwent reformation and multiplanar
reconstruction. An experienced radiologist (AL), who
had no access to the patients’ history, re-evaluated all
CT scans for study purposes. Scans were assessed for
pathological changes in the lung parenchyma, particulary
nodular infiltrates, halo signs, wedge-shaped pleural as-
sociated consolidation, peribronchial consolidation, focal
ground-glass opacities, diffuse ground-glass opacities,
caverns (air-crescent signs) and centrilobular nodules
(tree-in-bud pattern). Dense nodules with or without
halo-signs, air-crescent signs, and cavities were considered
as typical Aspergillus signs.
Data collection
The following details were collected from the electronic
patient data management system (PDMS, ICM, Dräger,
Lübeck, Germany): age, sex, diagnosis, comorbidities,
Simplified Acute Physiology Score II (SAPS II) and Se-
quential Organ Failure Assessment (SOFA) score, Acute
Physiology And Chronic Health Evaluation (APACHE II)
score at ICU admission, clinical, laboratory and radio-
logical data, previous treatments (e.g. corticosteroids, an-
tibiotics), antifungal treatment and medical interventions
(e.g. CT scan, bronchoscopy/BAL). The length of ICU
stay and the 28-day and 6-month mortality rates were
also recorded. Survival data were obtained from medical
records and telephone follow up.
Classification
All patients enrolled in the study were classified as proven
IPA, putative IPA, or colonization according to the
AspICU algorithm [10]. In patients with positive Aspergil-
lus culture (PAC group) the published protocol was used
[10]. For patients with negative Aspergillus culture in re-
spiratory tract samples (only positive galactomannan
(OPG) group) we proposed a modified AspICU algorithm
with positive galactomannan test as an additional entry cri-
terion (Additional file 1: Table S1). Hence, the diagnosis of
putative IPA and the status of colonization can be reached
by two entry criteria. Whenever antimycotic treatment was
implemented, patients were classified as being diagnosed
with clinical IPA.
Host factors putting the patient at risk of fungal infec-
tions were defined according to EORTC/MSG criteria [17]:
recent history of neutropenia, receipt of an allogeneic stem
cell transplant, prolonged use of corticosteroids (at a mean
minimum dose of 0.3 mg/kg/day of prednisone-equivalent
for 13 weeks), treatment with other recognized T cell
immunosuppressants (e.g. cyclosporine, TNF-α blockers,
specific monoclonal antibodies or nucleoside analogues)
during the past 90 days or inherited severe immunodefi-
ciency (e.g. chronic granulomatous disease or severe
combined immunodeficiency) [17]. Additionally, ac-
cording to classic risk factors in EORTC/MSG defini-
tions of fungal infections in ICU from 2015 [18],
severe chronic pulmonary disease and decompensated
liver cirrhosis were also considered as putting the patient
at risk of fungal infections.
Statistical analysis
Continuous variables are expressed as median (inter-
quartile range). Categorical variables are described as
the frequency of occurrence in each category (%). In
univariate analysis, categorical variables were compared
using Fisher’s exact or the likelihood ratio chi-squared
test. Continuous variables were compared using Student’s
t test. Overall survival was plotted using the Kaplan-Meier
method and compared by log-rank statistics. All tests
of significance were two-tailed, and a p value ≤0.05 was
considered significant. Statistical analyses were performed
using IBM® SPSS® Statistics 21.
Results and discussion
Study group
During the study period 8952 patients were admitted to
the Department of Intensive Care. Positive Aspergillus
tests (Aspergillus species in culture or positive galacto-
mannan in BALF) were obtained from lower respiratory
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tract samples (tracheal aspirate, n = 2; BALF, n = 89) in
91 critically ill patients who were therefore eligible to
participate in the study (incidence 10.2/1000 ICU admis-
sions). Six patients did not give consent, leaving 85 who
were included in the study.
Aspergillus species were detected in cultures of re-
spiratory tract samples (PAC group) in 43 patients
(50.6 % of all study patients). The most frequently
isolated species was Aspergillus fumigatus (n = 36, 83.7 %
of all patients with Aspergillus growth). Aspergillus niger
was isolated in three patients and in a further three
patients Aspergillus flavus (n = 1), Aspergillus nidulans
(n = 1) and Aspergillus terreus (n = 1) were isolated.
Forty-two patients had a positive galactomannan test
without growth of Aspergillus species in culture
(OPG group) (Additional file 1: Figure S1).
Patient characteristics
Table 1 shows baseline characteristics, underlying condi-
tions, admission diagnosis and treatment while in the ICU
and outcomes for the PAC and OPG groups. There were
no statistically significant differences in demographic data
or ICU scores between the two groups. Patients in the
OPG group had a shorter ICU stay before the first positive
Aspergillus result. Patients in the OPG group had a
shorter total ICU stay, were less often intubated, spent less
time on invasive ventilation, more often had neutropoenia
and were more likely to have received chemotherapy. The
PAC group were more likely to have received renal re-
placement therapy. There were no statistically significant
differences between the groups in extracorporeal mem-
brane oxygenation (ECMO) treatment or use of immuno-
suppressive agents. A total of 46 patients (54.1 %) received
more than 20 mg per day prednisolone-equivalent and 12
(14.1 %) received corticosteroids for more than 3 weeks.
Corticosteroid use was similar in both groups.
Diagnostic tests
Galactomannan
The median galactomannan titre in BALF was signifi-
cantly higher in the PAC group (EIA 5.9, IQR 3.2–5.7)
than in the OPG group (EIA 1.7, IQR 0.9–4.5) (p < 0.001)
(Table 2 and Additional file 1: Figure S2). There was no
statistically significant difference in positive galactoman-
nan test results from blood samples in the PAC group
(EIA 2.3, IQR 1.2–5.0) and the OPG group (EIA 1.0, IQR
0.7–3.1) (p = 0.181).
Aspergillus PCR
PCR assays from BALF were performed in 24 and 23 pa-
tients in the PAC and OPG groups, respectively. There
was a significantly higher percentage of positive Asper-
gillus PCR in the PAC group, with 62.5 % vs 17.3 % in
the OPG group.
Imaging
CT scans of the chest were performed on 40 patients
(93.0 %) in the PAC group and 41 patients (97.6 %) in the
OPG group. CT scans could not be performed in four pa-
tients due to their critical medical condition and use of
ECMO or interventional lung-assist (iLA) devices. There
was no difference between the frequency of typical Asper-
gillus signs in the PAC group (37.5 %) and OPG group
(36.6 %) (p = 0.932).
Histological examination
A postmortem examination was performed in four and
eight patients in the PAC and the OPG groups, respect-
ively. Histological examination of a specimen obtained
by transbronchial biopsy was available in one patient.
IPA was documented histologically in two patients, both
in the OPG group. Whether or not the failure to histo-
logically confirm the clinical diagnosis of IPA in the
other patients was due to the success of antimycotic
treatment remains unknown.
Classification
All patients were classified according to AspICU and
EORTC criteria [10, 17] (Fig. 1). In addition, the decision of
the attending physician to start antimycotic treatment was
taken as a clinical diagnosis of IPA. There were no statisti-
cally significant differences between the PAC and the OPG
group AspICU or EORTC criteria: 36 patients in the PAC
group (83.7 %) and 33 patients in the OGP group (78.6 %)
were classified as proven or putative IPA according to
AspICU and the modified AspICU clinical algorithm. The
number of patients with positive EORTC criteria for proven
or probable IPA was low, with 10 patients in the PAC group
(23.9 %) and 8 in the OPG group (19.3 %).
Antimycotic treatment
Overall, 63 patients (74.1 %) received antimycotic treat-
ment for IPA. Patients in the PAC group were more
likely to be treated for IPA than those in the OPG group
(88.4 % vs 59.5 %, p = 0.002; Fig. 2). Voriconazole was
the most commonly used antimycotic agent (given to
63.5 % of patients who received antimycotic treatment).
Voriconazole levels were measured at weekly intervals, and
the mean serum concentration was 2 mg/L (interquartile
range 1–3 mg/L) in the first 2 weeks, decreasing to 1 mg/L
(interquartile range 0–3 mg/L) in the third week. Only a
small number of patients received voriconazole for more
than 3 weeks (eight in week 4, five in week 5, four in week
6). The mean voriconazole concentration from weeks 3–6
was 2 mg/L (interquartile range 0–3 mg/L).
Outcome
The 28-day mortality was 38.8 % (32.6 % in the PAC
group vs 45.2 % in the OPG group). The overall 180-
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Table 1 Baseline characteristics, underlying conditions, laboratory values and outcome of critically ill patients with
Aspergillus-positive culture in respiratory tract samples (PAC group) and only positive galactomannan without Aspergillus
growth in the BALF (OPG group)
All patients PAC group OPG group P value
Variable (n = 85) (n = 43) (n = 42)
Male sex, n (%) 61 (71.8) 32 (74.4) 29 (69.0) 0.582
Age, years, median (IQR) 62 (52–72) 59 (51–76) 63 (53–71) 0.827
Body mass index, weight (kg)/height (m2), median (IQR) 25 (22–27) 25 (21–27) 24 (22–27) 0.853
ICU score, median (IQR)
SOFA 8 (5–10) 9 (5–11) 7 (5–10) 0.427
SAPS II 45 (36–55) 45 (35–57) 45 (37–54) 0.758
APACHE II 20 (17–25) 18 (16–25) 22 (17–25) 0.176
Underlying conditions, n (%)
Neutropenia 6 (7.1) 0 6 (14.3) 0.012
Hematological malignancy 21 (24.7) 7 (16.3) 14 (33.3) 0.068
Chemotherapy 30 (35.3) 10 (23.3) 20 (47.6) 0.019
Oncological malignancy 24 (28.2) 12 (28.6) 12 (27.9) 0.946
Allogeneic stem cell transplantation 11 (12.9) 4 (9.3) 7 (16.7) 0.351
Chronic obstructive pulmonary disease 13 (15.3) 6 (14) 7 (16.7) 0.728
HIV infection 3 (3.5) 0 3 (7) 0.241
Liver cirrhosis 7 (8.2) 5 (11.6) 2 (4.8) 0.433
Diabetes mellitus 9 (10.6) 7 (16.3) 2 (4.8) 0.084
Renal insufficiency 25 (29.4) 13 (30.2) 12 (27.9) 0.867
Solid organ transplant 10 (11.8) 4 (9.3) 6 (14.3) 0.520
Patients without classic risk factorsa n (%) 31 (36.5) 18 (41.9) 13 (31) 0.296
Treatment on ICU
ICU stay before first positive Aspergillus result, days, median (IQR) 4 (1–11) 7 (2–14) 3 (1–5) 0.007
ICU length of stay, days, median (IQR) 22 (13–41) 30 (17–51) 16 (10–25) 0.016
Invasive ventilation, n (%) 72 (84.7) 40 (93) 32 (76.2) 0.038
Invasive ventilation before first positive Aspergillus result, days, median (IQR) 1 (0–5) 3 (0–10) 1 (0–2) 0.005
Invasive ventilation, days, median (IQR) 10 (4–30) 19 (8–40) 7 (1–18) 0.003
Non-invasive ventilation before first positive Aspergillus result, days (IQR) 0 (0–1) 0 (0–1) 0 (0–1) 0.211
Non-invasive ventilation, days (IQR) 1 (0–4) 0 (0–2) 2 (0–5) 0.121
ECMO use, n (%) 12 (14.1) 5 (11.6) 7 (16.7) 0.549
ECMO, days, median (IQR) 13 (11–19) 20 (11–24) 12 (6–14) 0.074
Renal replacement therapy before first positive Aspergillus result, n (%) 23 (27.1) 16 (37.2) 7 (16.7) 0.033
Renal replacement therapy after first positive Aspergillus result, n (%) 41 (48.2) 26 (60.5) 15 (35.7) 0.022
Antibiotic treatment, n (%) 85 (100) 43 (100) 42 (100)
Immunosuppressionb, n (%) 50 (58.8) 29 (67.4) 21 (50) 0.102
Corticosteroid use, n (%)
Prednisolone ≥ 20 mg/day or equivalent 46 (54.1) 26 (60.5) 20 (47.6) 0.235
Prednisolone ≥ 20 mg/day or equivalent for more than 3 weeks 12 (14.1) 7 (16.3) 5 (11.9) 0.757
Inflammatory markers, median (IQR)
White blood cell count, 109/L 12 (7–17) 11 (9–17) 13 (5–17) 0.549
Procalcitonin, μg/l 2 (1–5) 1 (0–4) 2 (1–9) 0.138
CRP, mg/dl 145 (62–234) 131 (62–239) 159 (43–232) 0.683
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day mortality was 58.8 %. A total of 25 patients died
in each group, giving a mortality rate of 58.1 % in
the PAC group and 59.5 % in the OPG group (Fig. 2).
There was no significant difference in survival be-
tween the groups (Fig. 3).
Discussion
In this prospective study we examined the effects of
applying a standardized algorithm to diagnose IPA in crit-
ically ill patients treated in the ICU. Using the algorithm
prospectively ensured that the necessary diagnostic tests
and examinations (CT scan, bronchoscopy/BAL) were
done in a timely manner. We used the published AspICU
clinical algorithm to diagnose IPA [10] but modified
it by including a positive BALF galactomannan test as an
additional entry criterion. The main finding of our study is
that patients with laboratory-confirmed growth of Asper-
gillus species in culture (the entry criterion proposed by
Blot et al., [10]) and patients with a positive galactomannan
test from BALF but no growth of Aspergillus in culture
(modified AspICU clinical algorithm) had no differences in
outcome, baseline characteristics or admission data.
Table 1 Baseline characteristics, underlying conditions, laboratory values and outcome of critically ill patients with
Aspergillus-positive culture in respiratory tract samples (PAC group) and only positive galactomannan without Aspergillus
growth in the BALF (OPG group) (Continued)
Mortality, n (%)
28-day mortality 33 (38.8) 14 (32.6) 19 (45.2) 0.230
180-day mortality 50 (58.8) 25 (58.1) 25 (59.5) 1.000
SOFA Sequential Organ Failure Assessment, SAPS Simplified Acute Physiology Score, APACHE Acute physiology and Chronic Health Evaluation, ECMO
extracorporeal membrane oxygenation. aClassic risk factors: neutrophil abnormality, chronic airway abnormality, decompensated liver cirrhosis, treatment with
recognized T cell immunosuppressants and allogeneic stem cell transplant. bImmunosuppression: neutropenia, hematological malignancy, chemotherapy,
oncological malignancy, allogeneic stem cell transplantation, chronic obstructive pulmonary disease, HIV infection, liver cirrhosis, diabetes mellitus, renal
insufficiency, solid organ transplant and/or treatment with prednisolone ≥ 20 mg/day or equivalent
P values ≤0.05 are presented in bold
Table 2 Results of diagnostic tests in critically ill patients with Aspergillus-positive culture in respiratory tract samples (PAC group)
and only positive galactomannan without Aspergillus growth in the BALF (OPG group)
All patients PAC group OGP group P value
Variable (n = 85) (n = 43) (n = 42)
Galactomannan
Galactomannan test in BALF, positive, n (%) 77 (90.6) 35 (81.4) 42 (100) 0.049
Galactomannan test in BALF, titre EIA (IQR) 3.4 (1.0–6.3) 5.9 (3.2–7.0) 1.7 (0.9–4.5) <0.001
Galactomannan test in serum, positive, n (%) 16 (18.8) 11 (25.6) 5 (11.9) 0.096
Galactomannan test in serum, titre EIA (IQR) 1.9 (1.0–3.8) 2.3 (1.2–5.0) 1.0 (0.7–3.1) 0.181
Aspergillus-PCR in BALF
Performed, n 47 24 23
Positive, n (%) 19 (40.4) 15 (62.5) 4 (17.3) 0.002
Bronchoscopy
Aspergillus tracheobronchitis, n (%) 8 (9.4) 7 (16.3) 1 (2.4) 0.058
CT scan
Performed, n 81 40 41
Nodular infiltrate(s), n (%) 23 (28.4) 12 (30.0) 11 (26.8) 0.752
Halo sign, n (%) 11 (13.6) 4 (10.0) 7 (17.1) 0.519
Wedge-shaped pleura associated consolidations, n (%) 16 (19.8) 7 (17.5) 9 (22.0) 0.615
Focal ground-glass opacities (%) 26 (32.1) 13 (32.5) 13 (31.7) 0.939
Caverns/air-crescent sign, n (%) 8 (9.9) 6 (15.0) 2 (4.9) 0.155
Tree-in-bud pattern/centrilobular nodules, n (%) 14 (17.3) 5 (12.5) 9 (22.0) 0.379
Peribronchial consolidations, n (%) 46 (56.8) 21 (52.5) 25 (61.0) 0.441
Diffuse ground-glass opacities, n (%) 17 (21.0) 9 (22.5) 8 (19.5) 0.741
Lesions typical of invasive aspergillosis on CT scan, n (%) 30 (37.0) 15 (37.5) 15 (36.6) 0.932
EIA enzyme immunosassay, BALF bronchoalveolar lavage fluid, CT computed tomography, IQR interquantile range
P values ≤0.05 are presented in bold
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The major strength of our study was the completeness
of the diagnostic workup. All 85 patients underwent bron-
choscopy with BAL. On bronchoscopic examination, signs
of Aspergillus tracheobronchitis were seen in eight pa-
tients overall (9.4 %) but 7 of these were in the PAC group
and only one in the OPG group. A thoracic CT scan was
performed in 81 patients. CT in critically ill patients car-
ries the risk of intra-hospital transport, therefore, potential
benefits should outweigh the risks to justify the procedure
[19]. In fact, one third of the scans showed typical features
of Aspergillus. An important finding was that typical signs
of Aspergillus were detected with similar frequency in the
PAC and OPG groups.
The major strength of the modified algorithm was the
reduction of underdiagnosis of patients with IPA and
negative Aspergillus cultures. The diagnosis of IPA in
the ICU is notoriously difficult. The gold standard, histo-
pathological analysis, is often unavailable, not feasible or
considered too risky. In our study, we compared the
AspICU clinical criteria and EORTC/MSG criteria with
clinical diagnosis of IPA formulated as a decision to
treat. In our setting, the EORTC/MSG criteria would
result in a much lower yield (Fig. 1), resulting in under-
diagnosis of IPA. There was much greater agreement be-
tween patients diagnosed with IPA and the clinical
decision to treat when AspICU criteria were used. How-
ever, the AspICU clinical algorithm demands a positive
Aspergillus culture as an entry criterion [10]. However,
up to 50 % of IPA infections are not culture-positive
[20], and relying on a positive culture might result in
withholding treatment to patients with an active infec-
tion. Including the positive galactomannan test as an
entry criterion, we identified patients (the OPG group)
with the same risk factors, demographic data and out-
come as patients with positive fungal culture. This OPG
group had the same proportion of Aspergillus-positive
thoracic imaging as the culture-positive group as defined
by EORTC/MSG criteria. Interestingly, the only two pa-
tients with histologically proven IPA had a negative Asper-
gillus culture but positive BALF galactomannan antigen.
The detection of positive Aspergillus culture in BALF
was regarded as a stronger indicator of the presence of IPA
by clinicians and was more likely to trigger antimycotic
treatment than positive BALF galactomannan. However,
Fig. 1 Classification of all patients with positive Aspergillus culture (PAC group) and only positive galactomannan with negative culture (OPG group)
according to the Aspergillus algorithm for use in critically ill patients (AspICU) and European Organization for the Research and Treatment of Cancer
(EORTC) criteria. IPA invasive pulmonary aspergillosis
Fig. 2 Outcome of patients with proven and putative invasive pulmonary aspergillosis (IPA) according to the modified Aspergillus algorithm for
use in critically ill patients (AspICU). PAC patients with positive Aspergillus culture, OPG patients with only positive galactomannan with negative
culture, d day
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our study shows that patients with negative respiratory
tract culture but positive BALF antigen have the same
characteristics as patients with positive Aspergillus culture.
This suggests that such patients might benefit from
antimycotic therapy as much as patients with positive
Aspergillus culture.
We suggest that the integration of BALF galactoman-
nan could increase the diagnostic yield for IPA in ICU
patients. Recently published studies support the use of
galactomannan assays on BALF, serum and cerebro-
spinal fluid to initiate antimycotic therapy and to moni-
tor therapeutic success [20–25]. In ICU patients with
COPD, liver cirrhosis, or steroid medication, the sensi-
tivity of galactomannan detection in BALF was 88 % in
proven cases of IPA when applying a cutoff value of 0.5
[21]. In our cohort, steroid use was high; 46 patients
(54.1 %) received prednisolone ≥ 20 mg/day or an
equivalent for various indications (e.g. treatment of ex-
acerbation of COPD, immunosuppression after solid
organ transplantation or treatment or prevention of
raised intracranial pressure).
BALF galactomannan has been shown to have better
sensitivity in the diagnosis of IPA in critically ill patients
with COPD than serum galactomannan or Aspergillus
isolation from lower respiratory tract samples [26]. In
our study, only 16 patients (18.8 %), 14 of whom (87 %)
had putative aspergillosis, had a positive serum galacto-
mannan test, thus, its diagnostic value was only
moderate.
A possible limitation of this study is the incomplete
collection of samples to perform Aspergillus PCR (47/85).
We did find a significant difference between the PAC
group (15 patients positive, 62.5 %) and OPG group
(4 patients positive, 17.3 %) (p = 0.002) for PCR posi-
tive results. However, in our opinion it is not viable
to base a definitive exclusion of IPA only on a nega-
tive Aspergillus PCR.
The shortcomings of the EORTC/MSG criteria when
applied to ICU patients were addressed by a proposal for
the revised criteria [18]. According to the criteria,
proven aspergillosis is defined as clinical or radiological
abnormalities, consistent with a pulmonary infectious
disease process, that are otherwise unexplained in pa-
tients with neutrophil abnormality, chronic airway ab-
normality, decompensated liver cirrhosis, treatment with
recognized T cell immunosuppressants or allogeneic
stem cell transplant with cytology, direct microscopy
and/or culture from respiratory tract, showing Aspergil-
lus and/or galactomannan antigen index >0.5 in plasma/
serum or >1.0 in BALF. Applying these criteria, 33 pa-
tients in the PAC group (76.7 %) and 21 patients in the
OPG group (50.0 %) from our cohort were classified as
probably having aspergillosis (Additional file 1: Table S1).
Applying the proposed revised criteria resulted in a de-
crease in unclassified cases from 78.8 to 34.1 %. But
even if the revised EORTC/MSG criteria are used, pa-
tients without typical risk factors will not be identified.
In our study cohort, 31 patients (36.5 %) did not exhibit
the classic risk factors. There was no significant differ-
ence in the number of patients with class risk factors
between the groups (PAC, n = 18 (41.9 %) and OPG,
n = 13 (31 %) (p = 0.296) (Table 1).
The cutoff point for galactomannan antigen testing
in BALF has been widely debated. Receiver operating
characteristic curve analyses for the galactomannan
test in BALF by positive culture for Aspergillus species
produced an area under the curve (AUC) of 0.709
(Additional file 1: Figure S3). At the cutoff of a galacto-
mannan titer of 1.0 EIA, the sensitivity and specificity for
positive culture were 94.3 % and 38.1 %, respectively. For
the cutoff of 3.0 EIA, the sensitivity and specificity for
positive culture was 71.8 % and 61.9 %, respectively.
Our study has several limitations. The number of pa-
tients with histologically proven IPA was small. Pro-
spective studies with histological analysis as the gold
standard would be helpful [27]. However, diagnostic lung
biopsy is often not feasible in critically ill, ventilated pa-
tients who also often have impaired hemostasis and
thrombocytopenia. The number of patients included in
our study does not allow us to compare the outcome of
those who received antimycotic treatments and those
who did not. Mortality was high in both the PAC group
and the OPG group; however, the outcomes in our study
Fig. 3 Survival curve of critically ill patients with positive Aspergillus
culture in respiratory tract samples (PAC group) and only positive
galactomannan test in bronchoalveolar fluid (OPG group). Overall
survival was plotted using the Kaplan-Meier method. pos. positive
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were better than those published elsewhere [20, 21]. The
12-week mortality in the recent follow-up AspICU study
was 66 % and 73 % in patients with and without im-
munosuppression, respectively [14], compared with 180-
day mortality of 59 % in our study. One explanation
might be that the use of BALF galactomannan as a bio-
marker led to more timely antimycotic therapy and thus,
improved the outcome.
Conclusion
In critically ill patients, IPA is an emerging and serious in-
fection with high morbidity and mortality. Establishing the
diagnosis is therefore critical. However, the diagnosis of
IPA and its discrimination from Aspergillus colonization is
difficult. The traditional AspICU algorithm may lead to the
underdiagnosis of IPA by excluding patients with negative
Aspergillus cultures. Our study showed that the use of a
modified AspICU clinical algorithm with positive galacto-
mannan BALF as an additional entry criterion could in-
crease the diagnostic sensitivity for IPA in ICU patients.
Key message
 Using a positive galactomannan test in
bronchoalveolar lavage fluid as an additional entry
criterion for the AspICU clinical algorithm increases
diagnostic sensitivity for invasive pulmonary
aspergillosis in critically ill patients.
Additional file
Additional file 1: Includes a definition of the modified AspICU criteria, a
table containing patient allocation to the applied classifications, a flow
chart explaining the study layout, a box plot analysis of BALF Aspergillus
galactomannan titer, and a receiver operating curve analyses for
galactomannan test in BALF by positive culture for Aspergillus species.
(PDF 819 kb)
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